SG11202112399PA - Variant domains for multimerizing proteins and separation thereof - Google Patents

Variant domains for multimerizing proteins and separation thereof

Info

Publication number
SG11202112399PA
SG11202112399PA SG11202112399PA SG11202112399PA SG11202112399PA SG 11202112399P A SG11202112399P A SG 11202112399PA SG 11202112399P A SG11202112399P A SG 11202112399PA SG 11202112399P A SG11202112399P A SG 11202112399PA SG 11202112399P A SG11202112399P A SG 11202112399PA
Authority
SG
Singapore
Prior art keywords
separation
variant domains
multimerizing
proteins
multimerizing proteins
Prior art date
Application number
SG11202112399PA
Other languages
English (en)
Inventor
Kruif Cornelis Adriaan De
Peter Brian Silverman
Richard Bonneau
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of SG11202112399PA publication Critical patent/SG11202112399PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
SG11202112399PA 2019-05-09 2020-05-08 Variant domains for multimerizing proteins and separation thereof SG11202112399PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19173633 2019-05-09
PCT/NL2020/050298 WO2020226502A2 (en) 2019-05-09 2020-05-08 Variant domains for multimerizing proteins and separation thereof

Publications (1)

Publication Number Publication Date
SG11202112399PA true SG11202112399PA (en) 2021-12-30

Family

ID=66476558

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112399PA SG11202112399PA (en) 2019-05-09 2020-05-08 Variant domains for multimerizing proteins and separation thereof

Country Status (15)

Country Link
US (1) US20210054049A1 (zh)
EP (1) EP3966238A2 (zh)
JP (1) JP2022534674A (zh)
KR (1) KR20220017909A (zh)
CN (2) CN114430745A (zh)
AR (1) AR118898A1 (zh)
AU (1) AU2020268684A1 (zh)
BR (1) BR112021022405A2 (zh)
CA (1) CA3139402A1 (zh)
IL (1) IL287928A (zh)
MA (1) MA55884A (zh)
MX (1) MX2021013646A (zh)
SG (1) SG11202112399PA (zh)
TW (1) TW202108613A (zh)
WO (1) WO2020226502A2 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091871A1 (ru) * 2018-03-30 2021-06-22 Мерус Н.В. Поливалентное антитело

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
US7135287B1 (en) * 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
ES2442615T5 (es) 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
EP1737890A2 (en) * 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
US9670269B2 (en) * 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
EP3689912A1 (en) * 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP2556747B1 (en) 2008-06-27 2020-12-02 Merus N.V. Antibody producing transgenic mice
ES2572728T3 (es) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Anticuerpos anti-HER biespecíficos
AU2012323287B2 (en) * 2011-10-10 2018-02-01 Xencor, Inc. A method for purifying antibodies
NZ630551A (en) * 2012-04-20 2017-11-24 Merus Nv Methods and means for the production of ig-like molecules
EP3936521A1 (en) * 2013-03-15 2022-01-12 Xencor, Inc. Heterodimeric proteins
US10844127B2 (en) 2014-02-28 2020-11-24 Merus N.V. Antibodies that bind EGFR and ErbB3
JP6744292B2 (ja) * 2014-07-29 2020-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
MA41375A (fr) * 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
JP7041077B2 (ja) * 2016-06-10 2022-03-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 リジン結合体化免疫グロブリン
TW201920275A (zh) 2017-07-06 2019-06-01 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
TW201920657A (zh) 2017-07-06 2019-06-01 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
EP3649154A1 (en) 2017-07-06 2020-05-13 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
JP2020530028A (ja) 2017-08-09 2020-10-15 メルス ナムローゼ フェンノートシャップ ＥＧＦＲ及びｃＭＥＴに結合する抗体
EA202091871A1 (ru) 2018-03-30 2021-06-22 Мерус Н.В. Поливалентное антитело

Also Published As

Publication number Publication date
IL287928A (en) 2022-01-01
EP3966238A2 (en) 2022-03-16
CN114430745A (zh) 2022-05-03
US20210054049A1 (en) 2021-02-25
WO2020226502A2 (en) 2020-11-12
MX2021013646A (es) 2022-01-31
AU2020268684A1 (en) 2021-12-09
CN114702587A (zh) 2022-07-05
WO2020226502A3 (en) 2021-02-04
AR118898A1 (es) 2021-11-10
MA55884A (fr) 2022-03-16
KR20220017909A (ko) 2022-02-14
WO2020226502A9 (en) 2022-03-03
JP2022534674A (ja) 2022-08-03
BR112021022405A2 (pt) 2022-04-19
TW202108613A (zh) 2021-03-01
CA3139402A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
IL279510A (en) Progranulin-FC polypeptide fusion proteins and their uses
IL279505A (en) Chimeric transmembrane protein and its uses
IL278943A (en) Multi-specificity binding proteins and improvements thereof
IL265489B (en) Recombinant binding proteins and their uses
EP3287470A4 (en) Novel recombinant bi-functional fusion protein and preparation and application therefor
ZA202100125B (en) Novel fusion protein specific for cd137 and pd-l1
SG11202106771QA (en) Single-molecule protein and peptide sequencing
IL284687A (en) Novel fusion proteins specific for CD137 and GPC3
IL284679A (en) Multifunctional chimeric proteins and their use
ZA202100859B (en) Recombinant protein variants
IL284772A (en) Antibodies against variable *muc1 and uses thereof
GB201800334D0 (en) Modified protein
SG11202110400QA (en) Fusion protein and use thereof
EP3995508A4 (en) NOVEL MODIFIED IMMUNOGLOBULIN FC FUSION PROTEIN AND USE THEREOF
SG11202101904UA (en) Spd-1 variant - fc fusion proteins
EP3816181A4 (en) IMPROVED FVIII FUSION PROTEIN AND ITS USE
IL287928A (en) Variant sites for multimerization of proteins and their separation
ZA202102533B (en) Fusion protein
IL304317A (en) tgf–beta–rii binding proteins
GB201919294D0 (en) Antibodies or binding proteins
IL290715A (en) nkg2d fusion proteins and their use
EP3976630A4 (en) ACTRII-BINDING PROTEINS AND THEIR USES
EP3802566A4 (en) PROTEINS AND THEIR USE FOR NUCLEOTIDE BINDING
EP3801485A4 (en) PROTEIN AND PEPTIDE PURIFICATION PROCEDURES
EP3576767A4 (en) RECOMBINANT PROTEINS AND USES THEREOF